Cargando…

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination

Idarucizumab, a humanized monoclonal antibody fragment (Fab), provides rapid and sustained reversal of dabigatran-mediated anticoagulation. Idarucizumab and dabigatran are mainly eliminated via the kidneys. This analysis aimed to characterize the renal elimination of idarucizumab and investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glund, Stephan, Gan, Guanfa, Moschetti, Viktoria, Reilly, Paul, Honickel, Markus, Grottke, Oliver, Van Ryn, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714879/ https://www.ncbi.nlm.nih.gov/pubmed/29534609 http://dx.doi.org/10.1177/1076029618755947

Ejemplares similares

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
por: Glund, Stephan, et al.
Publicado: (2016)

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014)

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
por: Glund, Stephan, et al.
Publicado: (2016)

Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran
por: Grottke, O, et al.
Publicado: (2014)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
por: Grottke, Oliver, et al.
Publicado: (2014)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017)

Prothrombin complex concentrate restores haemostasis in a dabigatran anticoagulated polytrauma pig model
por: Honickel, M, et al.
Publicado: (2014)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
por: Yasaka, Masahiro, et al.
Publicado: (2017)

Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required
por: McBride, Lucy, et al.
Publicado: (2018)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
por: Mutzenbach, Johannes Sebastian, et al.
Publicado: (2016)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction
por: Kurdziel, Marta, et al.
Publicado: (2021)

Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
por: Kalmanovich, Eran, et al.
Publicado: (2021)

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
por: Xie, Dan, et al.
Publicado: (2021)

Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone
por: Uddin, Syed-Abdullah, et al.
Publicado: (2022)

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice
por: Sauter, Thomas C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pkprf1bt7lbdlt2ee69jjh850k